Andrea Wang-Gillam, Chief Medical Officer at Jacobio (US) Pharmaceuticals, Incorporated and an Associate Professor at Washington University, shared a post on LinkedIn about a recent article she and colleagues authored:
“Excited to share our new publication in Cancer Communication on glecirasib (KRAS G12C inhibitor).
The study demonstrated promising clinical benefit in PDAC, BTC and other KRAS G12C-mutant tumors, where treatment options remain limited.
Grateful to patients across regions who participated in these studies!
Congratulations to my co-authors for their dedication and insight.”
Title: Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials
Authors: Jian Li, Ting Deng, Yanhong Gu, Antonio Calles Blanco, Zhihua Li, Chunmei Bai, Lin Wu, Jing Huang, Xingya Li, Yu Yao, Zhengbo Song, Yongsheng Li, Lian Liu, Ligang Xing, Wenming Wu, Julia Martínez-Pérez, Ayala Hubert, Jon Zugazagoitia, Jian Zhang, Yongsheng Wang, Yanqiu Zhao, Guilan Wen, Guohao Xia, Diansheng Zhong, Xueqin Chen, Kuirong Jiang, Andrea Wang-Gillam, Yuli Ding, Sumei Liu, Zhiyue Rao, Xinghu Liu, Lin Shen
Read the Full Article in PubMed.
More posts featuring Andrea Wang-Gillam on OncoDaily.